HSE to consider access to weight loss drug Mounjaro

Mounjaro is the brand name for tirzepatide. It is a prescription medicine used to improve blood-sugar control in adults with type 2 diabetes and to support weight loss in people with obesity. The article describes it mainly as a weight-loss drug, but highlights benefits beyond weight reduction. Wider access could therefore affect diabetes, blood pressure, and other health risks.

Tirzepatide works on hormone pathways involved in appetite, digestion, and blood-sugar regulation. It can make people feel fuller, reduce food intake, and help the body respond more effectively to insulin. The article reports that studies found reduced progression to type 2 diabetes and that some people with diabetes could reach glycemic remission.

In Ireland, the HSE is considering whether eligible people should receive Mounjaro free or at reduced cost. Professor Donal O'Shea said eligibility could include people with a BMI of 27 or more plus conditions such as prediabetes or type 2 diabetes. Access would need careful management because demand and costs could be very large.

The HSE expert group will consider whether people who need tirzepatide should receive it free or at a reduced cost. Its recommendation will be based on the drug's clinical benefits and economic value. HSE management will make the final decision after hearing the expert group's evidence. Eli Lilly has already engaged with Irish authorities about a pricing offer.

If access expands, one option would be to provide the drug to people with a BMI above 30. Another would use a lower BMI threshold of 27, but require related conditions. These could include high blood pressure, cardiovascular disease, prediabetes, or type 2 diabetes. Professor Donal O'Shea said case-by-case prescribing would be ideal.

The decision matters because Mounjaro is currently mainly available to people who can afford it. Wider public support could reduce that inequality, but it could also create major costs for the State. The expert group is considering the evidence, while HSE management will decide whether and how access changes.

Professor Donal O'Shea said more than a million people could be eligible if Mounjaro became more widely available. That estimate shows the scale of the decision. Eligibility could be based on obesity alone, or on a lower BMI combined with health conditions. The exact number would depend on the rules eventually adopted by the HSE.

The financial impact could also be substantial. Professor O'Shea said wider access could cost the State upwards of €2–€3 billion. The figure reflects the potential number of patients and the expense of supplying treatment. Eli Lilly has offered a price reduction, which Professor Michael Barry described as significant. He said the medicine could be cost effective or close to it.

The spending debate includes possible future savings. Treatment may reduce diabetes, cardiovascular problems, and other illnesses, but those savings may not appear directly in the health-service budget. The HSE management decision will follow the expert group's evidence and determine how broadly the drug is funded.

The case for tirzepatide goes beyond losing weight. Professor Donal O'Shea linked it with benefits for blood pressure and insulin resistance, and said users could be less likely to develop diabetes or cancer. Professor Carel le Roux said the decision should focus on health gain and quality of life, rather than weight alone.

The article gives several concrete findings. It reports that the risk of developing diabetes could be reduced by 90%, blood pressure could fall by 8 mil mercury, and some people with diabetes could enter glycemic remission. International randomised controlled trials also showed a reduction in the risk of having a heart attack. These findings connect the medicine with several major health outcomes.

The evidence is influencing the HSE's value assessment. Professor Michael Barry said the price reduction made the drug cost effective or close to it. However, wider access still requires careful planning. Professor O'Shea warned about frailty and more falls after weight loss, and said treatment should be used in the right way.

BMI is one possible way to identify people for obesity treatment, but Professor Donal O'Shea said it can be a poor individual assessment of health. A simple BMI threshold may include people with different levels of illness and future risk. It may also fail to show whether excess weight is already affecting blood pressure, blood sugar, or the heart.

He suggested offering Mounjaro to people with a BMI of 27 or greater when they also have conditions such as hypertension, cardiovascular disease, prediabetes, or type 2 diabetes. This approach links eligibility to both body size and measurable health problems. It could direct treatment toward people who are more likely to gain important health benefits.

Professor O'Shea said prescribing ideally should happen case by case. That would allow clinicians to consider a person's wider health rather than applying one number to everyone. The HSE must still decide the rules, and the expert group is assessing clinical benefits, cost, and how access could be managed fairly.

Obesity treatment can be viewed as an investment in preventing later illness. If treatment lowers the risk of diabetes, heart disease, or other complications, people may need fewer costly services in the future. Professor Donal O'Shea said this could make spending billions worthwhile, even though the benefits may not appear immediately in the health-service budget.

He gave a practical example: preventing diabetes or avoiding a hip replacement would save future healthcare resources. The article also links tirzepatide with better blood pressure, insulin resistance, and diabetes outcomes. These changes could reduce the need for later treatment, although the article does not quantify those savings.

The financial challenge is that the State would pay for medicines now, while any savings could arrive years later or appear outside the service paying for treatment. Professor O'Shea said the investment could be “massively well spent”. HSE management will weigh these possible benefits against the estimated cost and the need for careful prescribing.

Metabolic disease is a broad term for conditions involving the body's handling of energy and blood sugar. Obesity can contribute to insulin resistance, where the body responds less effectively to insulin. This can raise blood sugar and increase the risk of prediabetes and type 2 diabetes. Metabolic problems can also occur alongside high blood pressure and cardiovascular disease.

The article presents these conditions as connected targets for tirzepatide. Professor O'Shea said the drug could improve insulin resistance and blood pressure, while reducing the likelihood of developing diabetes. Professor Carel le Roux said it could lower diabetes risk by 90% and help some people with diabetes reach glycemic remission. Trials also showed reduced heart-attack risk.

These links explain why supporters want the decision framed around health gain, not weight loss alone. Better metabolic health could improve quality of life and prevent illness. However, the article also notes possible frailty and falls after weight loss, so wider treatment would require monitoring and careful use.